Galecto, Inc. (GLTO)
GLTO Stock Price Chart
Explore Galecto, Inc. interactive price chart. Choose custom timeframes to analyze GLTO price movements and trends.
GLTO Company Profile
Discover essential business fundamentals and corporate details for Galecto, Inc. (GLTO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Oct 2020
Employees
5.00
Website
https://galecto.comCEO
Hans T. Schambye
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
GLTO Financial Timeline
Browse a chronological timeline of Galecto, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 7 Nov 2025
Earnings released on 5 Aug 2025
EPS came in at -$2.60 .
Earnings released on 8 May 2025
EPS came in at -$1.92 .
Earnings released on 19 Mar 2025
EPS came in at -$5.22 falling short of the estimated -$3.12 by -67.31%.
Earnings released on 1 Nov 2024
EPS came in at -$3.39 surpassing the estimated -$3.70 by +8.38%.
Stock split effective on 30 Aug 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Aug 2024
EPS came in at -$4.00 surpassing the estimated -$8.00 by +50.00%.
Earnings released on 29 Apr 2024
EPS came in at -$5.00 surpassing the estimated -$10.25 by +51.22%.
Earnings released on 8 Mar 2024
EPS came in at -$5.75 surpassing the estimated -$7.75 by +25.81%, while revenue for the quarter reached $1.20M .
Earnings released on 6 Nov 2023
EPS came in at -$7.50 surpassing the estimated -$11.75 by +36.17%.
Earnings released on 31 Jul 2023
EPS came in at -$10.25 surpassing the estimated -$15.00 by +31.67%.
Earnings released on 28 Apr 2023
EPS came in at -$12.75 surpassing the estimated -$14.00 by +8.93%.
Earnings released on 9 Mar 2023
EPS came in at -$13.75 surpassing the estimated -$14.25 by +3.51%.
Earnings released on 8 Nov 2022
EPS came in at -$13.50 surpassing the estimated -$17.00 by +20.59%.
Earnings released on 29 Jul 2022
EPS came in at -$16.75 surpassing the estimated -$17.25 by +2.90%.
Earnings released on 29 Apr 2022
EPS came in at -$16.75 falling short of the estimated -$0.61 by -2.65K%.
Earnings released on 17 Feb 2022
EPS came in at -$13.25 surpassing the estimated -$14.00 by +5.36%.
Earnings released on 4 Nov 2021
EPS came in at -$12.50 surpassing the estimated -$14.00 by +10.71%.
Earnings released on 5 Aug 2021
EPS came in at -$12.25 surpassing the estimated -$13.50 by +9.26%.
Earnings released on 4 May 2021
EPS came in at -$0.53 falling short of the estimated -$0.46 by -15.22%.
Earnings released on 29 Mar 2021
EPS came in at -$11.46 falling short of the estimated -$0.91 by -1.16K%.
Earnings released on 30 Oct 2020
EPS came in at -$11.53 .
GLTO Stock Performance
Access detailed GLTO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.